Recent

% | $
Quotes you view appear here for quick access.

Strata Skin Sciences, Inc. Message Board

  • b767cpt b767cpt Feb 7, 2013 10:46 AM Flag

    From AAD Digital Program

    Targeted therapies take aim at skin cancer

    A tool for early detection

    Complementing the dramatic advances in treating late-stage melanoma was the FDA’s approval of groundbreaking technology designed to help dermatologists detect melanoma in its earliest stage. MelaFind, a hand-held imaging device approved in November, projects light of 10 different wavelengths (from blue to near infrared) on a lesion. The resulting image is analyzed using an algorithm developed from a database of 10,000 biopsied lesions. A “positive” finding is considered evidence to support biopsy, not a diagnosis of melanoma. It is intended for use only by dermatologists who have completed a training program, and only on pigmented lesions meeting specific criteria.

    “Right now we’re kind of in the dark ages in terms of finding melanoma early,” said Dr. Rigel, who is on the scientific advisory committee for Mela Sciences, the makers of MelaFind. “It’s very subjective; we can’t quantify why a spot is melanoma but can only say ‘it looks like one.’ MelaFind is very easy to use, the results are available within a couple of seconds, and it’s not expensive. It’s been tested on a large data set and demonstrated a 98.4 percent sensitivity in identifying melanoma. I use dermoscopy, and this, to me, is like dermoscopy on steroids.” Dr. Halpern and Dr. Weinstock cautioned that the utility of MelaFind and its role in the dermatologist’s practice remain to be seen. “How they roll this out over the next year, what additional data they gather on how dermatologists are using it and is it proving helpful, are going to be absolutely critical to its diffusion into practice,” Dr. Halpern said. Dr. Rigel remarked that MelaFind could be particularly useful in patients who present with multiple lesions. “In a patient with 50 lesions, I could mark 20 of those that I think are potentially suspicious, and if three come out as positive I can biopsy those. What may happen over time is that you’ll start revising your own personal algorithm. But only time will tell, because there’s no other model out there like MelaFind in dermatology.” (For more discussion of MelaFind, see the article “Augmenting the naked eye” in the 2012 Buyer’s Guide.)

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I should have also included that Dr Rabinovitz "serves as Member of Scientific and Medical Advisory Committee of MELA Sciences, Inc."

    • "11:00 AM New Diagnostic Tools in the Clinical Diagnosis and Management of Patients with Melanoma - 2013 / Dr. Rabinovitz"

      This Dr. Harold S Rabinovitz is a physician with "Skin and Cancer Associates" in Plantation, Florida.
      They have a Melafind unit. Given his topic I think it's a safe bet he will talk about Melafind.

      This Doctor is one of the opinion leaders. Check out his credentials:

      "Harold S. Rabinovitz, M.D., is a Board Certified Dermatologist with his office located in Plantation, Florida. He performs Mohs Micrographic Surgery and Skin Surface Microscopy. Dr. Rabinovitz provides patients with the latest technology and expertise in the field of skin cancers.

      Dr. Rabinovitz graduated Cum Laude from Princeton University and received his medical degree from University of Miami School of Medicine. He performed his internship at Mt. Sinai Medical Center and completed his dermatology residency at New York University Medical Center.

      Dr. Rabinovitz served as Assistant Clinical Professor and as Associate Clinical Professor of Dermatology at University of Miami School of Medicine. Presently, he serves as Clinical Professor of Dermatology."

      • 4 Replies to aequitas45
      • sandale111@bellsouth.net sandale111 Feb 8, 2013 5:37 AM Flag

        "Harold S. Rabinovitz, M.D., is a Board Certified Dermatologist with his office located in Plantation, Florida. [He has] a Melafind unit"

        He sounds Sephardic.

      • aequitas
        Thanks. Feeling much better about this AAD convention now. Thanks to everyone for their input today. This is how a financial message board is supposed to function.
        regards endo

      • BUMP!

        ""11:00 AM New Diagnostic Tools in the Clinical Diagnosis and Management of Patients with Melanoma - 2013 / Dr. Rabinovitz"

        This Dr. Harold S Rabinovitz is a physician with "Skin and Cancer Associates" in Plantation, Florida.
        They have a Melafind unit. Given his topic I think it's a safe bet he will talk about Melafind.

        This Doctor is one of the opinion leaders. Check out his credentials:

        "Harold S. Rabinovitz, M.D., is a Board Certified Dermatologist with his office located in Plantation, Florida. He performs Mohs Micrographic Surgery and Skin Surface Microscopy. Dr. Rabinovitz provides patients with the latest technology and expertise in the field of skin cancers.

        Dr. Rabinovitz graduated Cum Laude from Princeton University and received his medical degree from University of Miami School of Medicine. He performed his internship at Mt. Sinai Medical Center and completed his dermatology residency at New York University Medical Center.

        Dr. Rabinovitz served as Assistant Clinical Professor and as Associate Clinical Professor of Dermatology at University of Miami School of Medicine. Presently, he serves as Clinical Professor of Dermatology."

      • Aequitas ... Great find ... Thanks for the information!

        Sentiment: Strong Buy

    • Thanks for the great post

    • B767
      Thanks, I missed that. Excellent due diligence. Is this going to be a presentation? Sometimes, at these conventions, papers are written and distributed by the convention organizers. If it is an actual presentation given by Dr. Rigel and the other doctors mentioned, my apologies to Dr. Gulfo.
      regards endo

 
SSKN
0.67-0.03(-3.87%)Jul 29 4:00 PMEDT